Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406232 · ClinicalTrials.gov registry record
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
A clinical trial of Breast Carcinoma and Invasive Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT05406232: Recruiting study of Breast Carcinoma and Invasive Breast Carcinoma, sponsored by M.D. Anderson Cancer Center.
NCT05406232 is a study of Breast Carcinoma and Invasive Breast Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 12 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05406232, a study of Breast Carcinoma and Invasive Breast Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.
Primary Outcome
Will be estimated with corresponding two-sided 80% confidence intervals. Also, marker levels at each time point and unstandardized effect sizes (arithmetic differences from baseline) across time points will be estimated along with 2-sided 80% confidence intervals.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
- RADIATION Radiation Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2026-12-31 |
What NCT05406232 shows while recruiting
NCT05406232 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT05406232 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05406232 about?
NCT05406232 is a clinical study titled "Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer". This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tum...
What is the current status of trial NCT05406232?
This trial is currently recruiting. The enrollment target is 12 participants. The study started on 2023-09-15. Estimated completion is 2026-12-31.
What conditions does trial NCT05406232 study?
This clinical trial studies the following conditions: Breast Carcinoma, Invasive Breast Carcinoma.
What interventions are being tested in trial NCT05406232?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05406232?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05406232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05406232's enrollment target sits among peer trials
12 104th of 106 higher than 3 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI